News in other languages: NEOVACS

27/10	Neovacs : Résultats semestriels 2026
20/10	Neovacs : Ajustement de la valeur nominale
16/10	Néovacs franchit une étape et entrevoit une potentielle transaction à 25 millions d'euros
16/10	Neovacs : Néovacs fait un point d’avancement sur la cession d’une partie de sa propriété intellectuelle et l’accompagnement dans sa valorisation pour un montant total pouvant dépasser 25 MEUR
06/10	Neovacs : Nouveau tirage sur la ligne de financement

More news

Managers and Directors: NEOVACS

Manager	Title	Age	Since
Hugo Brugière CEO	Chief Executive Officer	-	-
Alexandre Courtoux DFI	Director of Finance/CFO	-	01/10/2020
Laurent Reber CTO	Chief Tech/Sci/R&D Officer	56	-

Director	Title	Age	Since
Daniel Zagury CHM	Chairman	-	16/04/1993
Bernard Fanget BRD	Director/Board Member	-	-
Baudouin Hallo BRD	Director/Board Member	-	01/05/2020

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NEOVACS	-0.52%	-3.50%	-99.98%	-100.00%	17.2K
WUXI APPTEC CO., LTD.	+0.34%	-3.03%	+37.45%	+61.06%	64.14B
ARGENX SE	+0.98%	+2.68%	+12.25%	+83.90%	55.53B
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+105.71%	53.03B
IQVIA HOLDINGS INC.	-1.57%	-0.65%	+26.93%	+56.07%	45.99B
BEONE MEDICINES AG	-0.75%	-2.85%	+17.95%	+99.00%	42.45B
REVOLUTION MEDICINES, INC.	+0.35%	+0.95%	+226.56%	+932.53%	40.45B
CELLTRION, INC.	-0.26%	-4.20%	+10.86%	+45.18%	32.25B
GENMAB A/S	-2.07%	+42.73%	+103.77%	+90.26%	34.47B
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-8.79%	+22.58%	-5.63%	24.23B
Average	-0.48%	+2.77%	+37.17%	+136.81%	39.25B
Weighted average by Cap.	-0.21%	+3.13%	+49.49%	+160.79%

See all sector performances

NEOVACS is a major player in the therapeutic vaccines for the treatment of autoimmune and / or inflammatory diseases. Its proprietary products are vaccine candidates developed from its own technology platform for Kinoid products used in lupus disease and allergies. This innovative approach allows the patient's immune system to regulate the damage caused by overproduction of cytokines (active immunotherapy) such as IL-4/IL-13/IgE. The company also uses the skills of its experienced team to invest in companies developing innovative products (BioTech) and medical devices (MedTech).

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
30/10/26	EUR 0.0965	-0.52%	234,410
28/10/26	EUR 0.0970	+4.98%	205,639
27/10/26	EUR 0.0924	+2.67%	78,557
26/10/26	EUR 0.0900	-6.35%	70,817
23/10/26	EUR 0.0961	-3.90%	27,636

Real-time Euronext Paris

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Euronext Paris 03:55:00 30/10/26 am AEDT			5-day change	1st Jan Change
0.0965 ^EUR	-0.52%		-3.50%	-99.89%

30/06	Neovacs bolsters its strategic intellectual property portfolio
30/04	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI

Market Cap	4.09K 4.56K 3.78K 3.42K 6.4K 434K 6.47K 45.2K 18K 227K 17.1K 16.74K 721K	P/E 2023 *	-	P/E 2024	-
Enterprise Value	-201K -224K -186K -168K -314K -21.34M -318K -2.22M -885K -11.16M -841K -823K -35.44M	EV / Sales 2023	-	EV / Sales 2024	-
Free-Float	2.32%	Yield 2023 *	-	Yield 2024	-

Markets		Quality
Euronext Paris	ALNEV	Real-time
Deutsche Boerse AG	0LW1	Delayed
Boerse Muenchen	0LW1	Real-time
Börse Stuttgart	0LW1	Delayed

30/06	Neovacs bolsters its strategic intellectual property portfolio
30/04	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
30/04	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11/02	Neovacs S.A. announced that it has received ?0.25 million in funding from Hanover Square Investments Pte Limted	CI
21/11	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
21/10/25	Neovacs S.A. announced that it expects to receive ?0.25 million in funding	CI
12/08/25	Neovacs S.A. announced that it has received ?0.25 million in funding from European High Growth Opportunities Manco S.A.	CI
30/04/25	Neovacs S.A. Auditor Raises 'Going Concern' Doubt	CI
30/04/25	Neovacs S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
17/03/25	Neovacs S.A. announced a financing transaction	CI
04/02/25	Neovacs: consideration of delisting, share price surges
04/11/24	Neovacs S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
02/11/24	Tech's Tangled Path with Microsoft

NEOVACS Stock

Stocks

ALNEV

FR0014018EV4

Biotechnology & Medical Research

Valuation: NEOVACS

Chart: NEOVACS

Latest news: NEOVACS

News in other languages: NEOVACS

Quotes and Performance

Price Extremes

Managers and Directors: NEOVACS

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

1 day	-0.52%
1 week	-3.50%
Current month	-51.75%
1 month	-54.09%
3 months	-87.93%
6 months	-95.18%
Current year	-99.89%

1 week	0.09	0.11
1 month	0.09	0.22
Current year	0.09	267
1 year	0.09	500
3 years	0.09	32,000,000
5 years	0.09	351,920,000
10 years	0.09	351,920,000

Date	Insider	Type	Main position	Quantity	% Market Cap.
27/2/21	Hugo Brugière	Sell	Chief Executive Officer	2,505,144	1.3796%
23/2/21	Hugo Brugière	Sell	Chief Executive Officer	6,391,053	3.5196%
23/2/21	Hugo Brugière	Sell	Chief Executive Officer	1,108,947	0.6107%

	2023	2024
Net sales	533K 595K 493K 447K 834K 56.62M 845K 5.9M 2.35M 29.63M 2.23M 2.18M 94.06M	434K 484K 401K 363K 679K 46.06M 687K 4.8M 1.91M 24.1M 1.81M 1.78M 76.52M
Net income	-8.74M -9.75M -8.08M -7.32M -13.68M -928M -13.84M -96.65M -38.5M -486M -36.57M -35.8M -1.54B	-32.91M -36.69M -30.43M -27.56M -51.49M -3.49B -52.11M -364M -145M -1.83B -138M -135M -5.8B
Net Debt	-237K -264K -219K -198K -370K -25.11M -374K -2.61M -1.04M -13.14M -989K -968K -41.71M	-205K -229K -190K -172K -321K -21.77M -325K -2.27M -903K -11.39M -858K -840K -36.17M